2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
08/09/17Editas Medicine Announces Second Quarter 2017 Results and Update
Leber Congenital Amaurosis type 10 (LCA10) product candidate EDIT-101 made significant progress toward clinical trials Achieved research milestone in Juno Therapeutics, Inc., collaboration CAMBRIDGE, Mass., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today reported financial results for the second quarter ended June 30, 2017, and provided an update on recent achievements and upcoming events. “This quarter, we made critical progres... 
 Printer Friendly Version
08/09/17Editas Medicine Achieves Milestone Under Juno Therapeutics Collaboration for Technical Progress Towards Overcoming the Tumor Microenvironment
CAMBRIDGE, Mass., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced today that it achieved a second milestone under its collaboration with Juno Therapeutics, Inc. (NASDAQ:JUNO). The most recent milestone results from the Company’s technical progress towards overcoming the tumor microenvironment in a research program to create engineered T cells with chimeric antigen receptors (CAR) and T cell receptors (TCR) to treat cancer. Impr... 
 Printer Friendly Version
08/07/17Editas Medicine to Host Conference Call Discussing Second Quarter 2017 Corporate Update and Results
CAMBRIDGE, Mass., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, August 9th, 2017, at 5:00 p.m. ET to discuss a corporate update and results for the second quarter of 2017. To access the call, please dial 844-348-3801 (domestic) or 213-358-0955 (international) and provide the passcode 59340161. A live webcast of the presentation will be available on the Inv... 
 Printer Friendly Version
06/13/17Editas Medicine to Participate in Investor Conferences in June
CAMBRIDGE, Mass., June 13, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor conferences in June.  Details are as follows: JMP Securities Life Sciences Conference Date: Tuesday, June 20, 2017 Panel: Gene Editing - Pushing the Frontier for Curing Disease Time: 9:00 a.m. ET Location: New York Gold... 
Download PDFPrinter Friendly Version
05/31/17Editas Medicine Names Andrew Hirsch to Board of Directors
CAMBRIDGE, Mass., May 31, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of Andrew Hirsch to its board of directors, effective immediately. Mr. Hirsch will also serve as chairman of the audit committee of the board.  He is currently Chief Financial Officer of Agios Pharmaceuticals. “Andrew’s deep experience in biotechnology spans strategy, finance, and operations, and I am pleased to welcome him to our board of... 
Download PDFPrinter Friendly Version
05/15/17Editas Medicine Announces First Quarter 2017 Results and Update
Entered strategic R&D alliance with ophthalmology leader Allergan to develop and commercialize ground-breaking medicines for patients with serious eye diseases Completed successful follow-on offering of common stock raising $104 million in gross proceeds Presented new data at the American Society of Gene & Cell Therapy Annual Meeting demonstrating advancements in translating CRISPR technology into medicines for eye and blood diseases CAMBRIDGE, Mass., May 15, 2017 (GLOBE NEWSWIRE) -- Edit... 
Download PDFPrinter Friendly Version
05/13/17Editas Medicine Demonstrates First Achievement of In Vivo Editing in Non-human Primate Retinas
Editing rate reported at ASGCT has potential to translate into a transformative therapy for LCA10 patients CAMBRIDGE, Mass., May 13, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from a pre-clinical study demonstrating the first achievement of efficient editing of the CEP290 gene in the retina of non-human primates. The results of this study further reinforce Editas Medicine’s belief in the transformative potential of i... 
Download PDFPrinter Friendly Version
05/11/17Editas Medicine Announces Pre-Clinical Data for Program to Treat Sickle Cell Disease and Beta-Thalassemia
CAMBRIDGE, Mass., May 11, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from its pre-clinical hematopoietic stem cell (HSC) program confirming the potential for CRISPR-based editing to treat sickle cell disease and beta-thalassemia. In an oral presentation today at the 20th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in Washington, D.C., the Company presented data demonstrating a substantial inc... 
Download PDFPrinter Friendly Version
05/08/17Editas Medicine to Host Conference Call Discussing First Quarter 2017 Corporate Update and Results
CAMBRIDGE, Mass., May 08, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday, May 15, 2017, at 5:00 p.m. ET to discuss a corporate update and results for the first quarter of 2017. To access the call, please dial 844-348-3801 (domestic) or 213-358-0955 (international) and provide the passcode 17355274. A live webcast of the presentation will be available on the Investors & ... 
Download PDFPrinter Friendly Version
05/08/17Editas Medicine to Present at Investor Conferences in May
CAMBRIDGE, Mass., May 08, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor conferences in May.  Details are as follows: Bank of America Merrill Lynch 2017 Health Care Conference Date:     Wednesday, May 17, 2017 Forum:     Panel Discussion on Gene Therapy and Gene Editing Time:     4:40 p.... 
Download PDFPrinter Friendly Version
04/24/17Editas Medicine to Present New Data Demonstrating Advancements for Translating CRISPR Technologies into Medicines at the American Society of Gene & Cell Therapy Annual Meeting
Oral presentation of first achievement of in vivo retinal gene editing in non-human primates Oral presentation of results demonstrating the potential of CRISPR/Cas9 gene editing to treat sickle cell disease and beta-thalassemia CAMBRIDGE, Mass., April 24, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that six scientific abstracts have been accepted for presentation at the 20th Annual Meeting of the American Society of Gene &... 
Download PDFPrinter Friendly Version
03/16/17Editas Medicine, Inc. Announces Pricing of $90 Million Offering of Common Stock
CAMBRIDGE, Mass., March 16, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the pricing of an underwritten offering of 4,000,000 shares of its common stock at a price to the public of $22.50 per share. The gross proceeds to Editas Medicine from this offering are expected to be approximately $90 million, before deducting underwriting discounts and commissions and other estimated offering expenses. Editas Medicine has granted the un... 
Download PDFPrinter Friendly Version
03/15/17Editas Medicine, Inc., Announces Proposed Offering of Common Stock
CAMBRIDGE, Mass., March 15, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it intends to offer and sell 4,000,000 shares of its common stock in an underwritten public offering. Editas Medicine intends to grant the underwriters a 30-day option to purchase up to an additional 600,000 of shares of its common stock. All of the shares in the offering are to be sold by Editas Medicine. Editas Medicine intends to use the net proce... 
Download PDFPrinter Friendly Version
03/14/17Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing Medicines for Eye Diseases
– Brings Together Eye Care and CRISPR Innovators to Develop Transformative Medicines for Patients – – Provides Allergan Exclusive Access to Multiple Editas Medicine Ocular Programs Based on its Unparalleled CRISPR Genome Editing Platform – – Reinforces Allergan’s Continued Commitment to Developing Innovative Treatments fo... 
Download PDFPrinter Friendly Version
03/07/17Editas Medicine Announces Fourth Quarter and Full Year 2016 Results and Update
Recent, highly favorable U.S. Patent and Trademark Office decision affirms and upholds fundamental CRISPR/Cas9 issued patents Extended CRISPR technology leadership with addition of novel and differentiated Cpf1 system, advanced forms of Cas9 Achieved in vivo proof-of-editing of non-human primate retina in LCA10 program CAMBRIDGE, Mass., March 07, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today reported financial results for the fourth qu... 
Download PDFPrinter Friendly Version
03/03/17Editas Medicine Announces Departure of Chief Operating Officer
CAMBRIDGE, Mass., March 03, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that its Chief Operating Officer, Alexandra Glucksmann, Ph.D., will be leaving the Company, effective March 31. Dr. Glucksmann’s responsibilities will be reallocated among current members of the Company’s management team. “On behalf of the entire Editas team, I sincerely thank Sandra for her countless contributions since the company’s inception,” said K... 
 Printer Friendly Version
02/28/17Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2016 Corporate Update and Results
CAMBRIDGE, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday, March 7, 2017, at 5:00 p.m. ET to discuss a corporate update and results for the fourth quarter and full year of 2016. To access the call, please dial 844-348-3801 (domestic) or 213-358-0955 (international) and provide the passcode 81030032. A live webcast of the presentation will be available o... 
Download PDFPrinter Friendly Version
02/28/17Editas Medicine Joins Global Movement to Raise Awareness on Rare Disease Day 2017
Editas Medicine Joins EURORDIS, NORD, and Other International Organizations to Underscore Importance of Research in Developing Treatments for Rare Diseases CAMBRIDGE, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced the company has joined forces with 30 million Americans and health care advocates around the world today for Rare Disease Day®. Rare Disease Day is an annual awareness day dedicated to elevating public unders... 
Download PDFPrinter Friendly Version
02/27/17Editas Medicine to Present at Investor Conferences in March
CAMBRIDGE, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor conferences in March.  Details of the presentations are as follows: Cowen & Company 37th Annual Healthcare Conference Date:     Monday, March 6, 2017 Time:     2:40 p.m. ET Location:     Boston ... 
Download PDFPrinter Friendly Version
02/15/17Editas Medicine Announces U.S. Patent and Trademark Office Decision Favorable to Broad Institute in CRISPR Interference
CAMBRIDGE, Mass., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT) announced today that the U.S. Patent and Trademark Office (USPTO) issued a favorable decision in the CRISPR interference between the University of California, the University of Vienna, Emmanuelle Charpentier and the Broad Institute, Inc. (Broad) regarding certain CRISPR-Cas9 patents the Company exclusively licenses from Broad. The USPTO granted Broad’s Motion for No Interference in Fact, ending the interfer... 
Download PDFPrinter Friendly Version
02/10/17Editas Medicine to Present at Upcoming February Investor Conferences
CAMBRIDGE, Mass., Feb. 10, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will present a company overview at two upcoming investor conferences in February.  Details of the presentations are as follows: 19th Annual BIO CEO & Investor Conference Date: Monday, February 13, 2017 Time: 3:00 p.m. ET Location: New York City     ... 
Download PDFPrinter Friendly Version
01/09/17Editas Medicine Reports on Recent Progress and 2017 Goals at J.P. Morgan Healthcare Conference
-    Company Achieves In Vivo Proof-of-Editing in the Retina of Non-Human Primates    -  -    Unparalleled Genome Editing Platform Includes Cpf1 and Advanced Forms of Cas9    - CAMBRIDGE, Mass., Jan. 09, 2017 (GLOBE NEWSWIRE) -- In a presentation to investors on Wednesday, January 11, 2017 at 11:30am (PST) at the 35th Annual J.P. Morgan Healthcare Conference, Editas Medicine, Inc. (NASDAQ:EDIT) President and CEO Katrine Bosley will outline the Company’s progress on developing medicines a... 
Download PDFPrinter Friendly Version
01/04/17Editas Medicine to Present at the 35th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a question and answer session at the 35th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017, at 11:30 a.m. PT in San Francisco, CA. A live webcast of the presentation and question and answer session will be available on the Investors & Media section of the Editas website at www.edi... 
Download PDFPrinter Friendly Version
Print Page    E-mail Page    RSS    E-mail Alerts